Archean Chemical Industries Q2 Revenue Rises 26% to Rs 302 Crore

Archean Chemical Industries Limited reported 26% year-on-year revenue growth to Rs 302 crore in Q2 FY27, led by export growth and a 76% rise in bromine segment revenue to Rs 127.5 crore. The September-quarter update also outlined progress in silicon carbide semiconductors and zinc-bromide energy storage.

What did Archean Chemical Industries report for Q2 FY27?

Archean Chemical Industries reported total revenue of Rs 302 crore for Q2 FY27, a 26% increase from the corresponding quarter of the previous year, according to its earnings call presentation. The company attributed the increase to an improved product mix and export growth, with bromine and bromine derivatives emerging as a key contributor.

The company also disclosed standalone total income of Rs 305.4 crore for the quarter ended September 30, 2026, compared with Rs 231.8 crore in Q2 FY26. Standalone EBITDA increased to Rs 89.3 crore from Rs 76.0 crore, while standalone profit after tax rose to Rs 43.2 crore from Rs 38.5 crore. Earnings per share for the quarter stood at Rs 3.50.

On a consolidated basis, the presentation reported total income of Rs 301.6 crore, up 25.9% year on year. Consolidated EBITDA was Rs 74.5 crore, a 7.9% increase, and profit before tax rose 14.6% to Rs 45.7 crore. The company’s reported figures distinguish between standalone and consolidated performance, which can result in different income and profit amounts.

How did the bromine business support quarterly growth?

The bromine and bromine derivatives business supported Archean Chemical Industries’ quarterly growth, with segment revenue rising 76% year on year to Rs 127.5 crore. This performance was cited alongside export growth and a better product mix as a driver of the company’s overall revenue increase.

Bromine is one of the company’s core chemical businesses, making its performance relevant to the Q2 result. The reported increase shows that the segment made a larger contribution during the quarter, although the presentation does not provide volume data, segment profitability, or a geographical split of sales.

The company said it expects operating and EBITDA margins to improve through expanded capacity and a higher share of value-added products. This is an outlook stated in the presentation rather than a reported financial result. The Q2 numbers show EBITDA growth, but consolidated EBITDA growth of 7.9% was lower than consolidated income growth of 25.9%.

What are Archean Chemical Industries’ new growth initiatives?

Archean Chemical Industries has started construction at its SiCSem site and made its pilot battery facility in the United Kingdom operational. These projects form part of its stated diversification into silicon carbide semiconductor materials and zinc-bromide energy storage solutions.

The SiCSem project places the company in a semiconductor-related area beyond its established chemical operations. The update confirms that construction has commenced, but it does not disclose project cost, commercial production timing, expected capacity, or projected revenue contribution.

The operational pilot battery facility in the UK relates to zinc-bromide energy storage. A pilot facility is an early-stage operational milestone, and the presentation does not state commercial sales, customer contracts, production scale, or profitability from this activity. Investors will therefore need to distinguish these development initiatives from the company’s current reported chemical revenue.

When were the Q2 FY27 results approved and what is next?

Archean Chemical Industries’ board reviewed and approved the unaudited Q2 and H1 FY27 results on October 29, 2026, for the quarter and half year ended September 30, 2026. The company has scheduled its earnings call for November 3, 2026, at 2:30 PM IST, where management is expected to discuss the quarterly and half-year performance.

For the half year, standalone total income was Rs 637.4 crore and standalone profit after tax was Rs 83.7 crore. Consolidated total income for the same period was Rs 634.4 crore, while consolidated profit after tax was Rs 61.7 crore. The unaudited standalone cash flow statement showed Rs 141.9 crore of net cash generated from operating activities during H1 FY27.

The same cash flow statement recorded investing cash outflow of Rs 141.8 crore and financing cash inflow of Rs 20.5 crore for the half year. Net cash and cash equivalents increased by Rs 20.6 crore. These figures provide context for the company’s ongoing investment activity, including its announced new-business initiatives.

Why do these results matter to investors?

The Q2 update matters because Archean Chemical Industries reported growth in its established chemical operations while progressing projects in silicon carbide and battery storage. The bromine segment’s 76% revenue increase to Rs 127.5 crore was the strongest segment-specific figure disclosed in the presentation and was central to the quarter’s revenue growth.

For investors, the main reported financial measures are the 26% rise in revenue to Rs 302 crore, standalone EBITDA of Rs 89.3 crore, and standalone PAT of Rs 43.2 crore. The difference in growth rates across revenue and consolidated EBITDA also makes margins an important area to track in subsequent disclosures.

The new projects add potential revenue diversification, but their financial contribution has not been disclosed. Construction at the SiCSem site and the UK pilot facility’s operational status are execution milestones, not evidence of commercial-scale revenue. The scheduled earnings call may offer further management commentary on timelines, capital allocation, capacity and market demand.

Conclusion

Archean Chemical Industries’ Q2 FY27 presentation showed a quarter of higher revenue, supported by export growth, product mix and a sharp increase in bromine segment revenue. Standalone profitability also increased year on year, while the company continued to report different financial outcomes under standalone and consolidated measures.

The next disclosed event is the November 3, 2026 earnings call. Investors will watch for management’s details on bromine demand, margin progression, the SiCSem construction timeline, the UK battery pilot’s commercial path and the investment required for these projects.